# Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

> **NCT00278993** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 108 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** E7389

## Key facts

- **NCT ID:** NCT00278993
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278993, "Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00278993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*